Translational Session
Therapeutics in AKI: From Bench to Bedside, Including the Burton D. Rose, MD, Endowed Lectureship
November 08, 2025 | 02:00 PM - 04:00 PM
Location: General Assembly B, Convention Center
Session Description
Despite a lack of pharmacological therapeutics for AKI, this last year has seen significant advances of potential therapeutic agents. Several new or repurposed agents are undergoing clinical trials for prevention and treatment of AKI. This session provides an overview of the mechanistic justification for the use of these agents and the clinical trial data regarding their performance in AKI.
ASN gratefully acknowledges Wolters Kluwer (publisher of UpToDate), the Beth Israel Deaconess Medical Center Department of Medicine Foundation, the Rose Family, and several of Dr. Rose's colleagues for supporting this lectureship.
Learning Objective(s)
- Describe novel preclinical therapeutic agents for AKI and next steps for translation to human studies
- Compare new therapeutic agents studied in clinical populations and their application to individual patients
- Identify opportunities and challenges in AKI research to improve outcomes
Learning Pathway(s)
- AKI and Critical Care
- Kidney Biology and Physiology
Moderators
Presentations
- Epigenetic Reprogramming in AKI
02:00 PM - 02:30 PM
- Angiopoietin-Tie2 Signaling in Ischemic AKI
02:30 PM - 03:00 PM
- Intravenous Amino Acids for Kidney Protection in Cardiac Surgery
03:00 PM - 03:30 PM
- Delayed Remote Ischemic Preconditioning: Extending the Window for AKI Protection: The Burton D. Rose, MD, Endowed Lectureship
03:30 PM - 04:00 PM